Prognosis of EGFR-mutant Lung Adenocarcinoma Patients With Malignant Pleural Effusion Receiving First-line EGFR-TKI Therapy Without Pleurodesis: A Single-institute Retrospective Study

2020 ◽  
Vol 40 (2) ◽  
pp. 1117-1121
Author(s):  
KOSUKE KASHIWABARA ◽  
SHINJI FUJI ◽  
SHINSUKE TSUMURA ◽  
KAZUHIKO SAKAMOTO
Keyword(s):  
Retrospective Study ◽  
Pleural Effusion ◽  
Lung Adenocarcinoma ◽  
Malignant Pleural Effusion ◽  
First Line ◽  
Egfr Mutant ◽  
Egfr Tki

scholarly journals Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion

Oncogene ◽  
2006 ◽  
Vol 25 (31) ◽  
pp. 4300-4309 ◽  
Author(s):  
H-H Yeh ◽  
W-W Lai ◽  
H H W Chen ◽  
H-S Liu ◽  
W-C Su
Keyword(s):  
Pleural Effusion ◽  
Lung Adenocarcinoma ◽  
Malignant Pleural Effusion

scholarly journals Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma

2019 ◽  
Vol 30 ◽  
pp. ix164 ◽  
Author(s):  
C.S. Chai ◽  
C.K. Liam ◽  
O. Po Lin ◽  
Y.K. Pang ◽  
G.F. Ho ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
First Line ◽  
Egfr Mutant ◽  
Line Setting
Sign in / Sign up

Export Citation Format

Share Document